Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
Posted: November 7, 2020 at 8:56 am
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –
See the original post:
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
Related Post
- Alimera Sciences Reports Fourth Quarter and 2020 Results - February 25th, 2021
- 10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event - February 25th, 2021
- GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results - February 25th, 2021
- Seer to Present at the Cowen 41st Annual Healthcare Conference - February 25th, 2021
- Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference - February 25th, 2021
- Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy - February 25th, 2021
- CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 25th, 2021
- ERYTECH to Participate in Upcoming Virtual Investor Conferences in March - February 25th, 2021
- vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - February 25th, 2021
- Antares Pharma to Present at Two Upcoming Investor Conferences - February 25th, 2021
- Valneva Reports FY 2020 Results and Major Corporate Achievements - February 25th, 2021
- Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of... - February 25th, 2021
- argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 - February 25th, 2021
- Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - February 25th, 2021
- LIDDS and Pharmidea signs manufacturing agreement - February 25th, 2021
- DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate... - February 25th, 2021
- LIDDS Interim report January – December 2020 - February 25th, 2021
- Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 25th, 2021
- Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results - February 25th, 2021
- SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update - February 25th, 2021
- Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference - February 19th, 2021
- Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights - February 19th, 2021
- Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update - February 19th, 2021
- Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine - February 19th, 2021
- Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021 - February 19th, 2021
- Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern... - February 19th, 2021
- Codexis to Present at Upcoming Virtual Healthcare Conferences - February 19th, 2021
- Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference - February 19th, 2021
- Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives - February 19th, 2021
- MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call - February 19th, 2021
- Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy - February 19th, 2021
- Harvard Bioscience Schedules Fourth Quarter 2020 Earnings Conference Call for March 10, 2021 at 8:00 AM ET - February 19th, 2021
- Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line... - February 19th, 2021
- DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference - February 19th, 2021
- Olainfarm expands presence in Ukraine to be closer to the clients - February 19th, 2021
- Vistin Pharma ASA: Fourth quarter and preliminary 2020 financial results - February 19th, 2021
- Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities - February 19th, 2021
- Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST) - February 19th, 2021
- Novartis Entresto® granted expanded indication in chronic heart failure by FDA - February 17th, 2021
- ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020 - February 17th, 2021
- Tower One Provides Construction and Business Update for the Month of January 2021 - February 17th, 2021
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update - February 17th, 2021
- Lumos Pharma Announces Changes to its Board of Directors - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels - February 17th, 2021
- Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 17th, 2021
- Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference - February 17th, 2021
- Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - February 17th, 2021
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 - February 17th, 2021
- Aleafia Health Announces $15 Million Bought Deal Offering of Units - February 17th, 2021
- Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - February 17th, 2021
- Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side - February 17th, 2021
- GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference - February 17th, 2021
- CohBar to Present at the BIO CEO & Investor Digital Conference - February 9th, 2021
- One World Pharma Secures $3 Million Investment Commitment From ISIAH International - February 9th, 2021
- Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in... - February 9th, 2021
- Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation... - February 9th, 2021
- Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics - February 9th, 2021
- Agenus Announces Agenus Insights - Virtual R&D Miniseries - February 9th, 2021
- Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan - February 9th, 2021
- The Capital Group holds 10.03% of Galapagos shares - February 9th, 2021
- Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March - February 9th, 2021
- Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to... - February 9th, 2021
- Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference - February 9th, 2021
- Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth - February 9th, 2021
- Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules - February 9th, 2021
- Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update - February 9th, 2021
- Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares - February 9th, 2021
- Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of... - February 9th, 2021
- GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of... - February 9th, 2021
- Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering - February 9th, 2021
- Andy Hurley Named Agenus Chief Commercial Officer - February 9th, 2021
- FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma - February 9th, 2021
- Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product - February 5th, 2021
- Silence Therapeutics plc Announces $45 Million Private Placement - February 5th, 2021